Clinical Trial

NWRD09 for HPV-16 Related Cervical HSIL

Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated July 2, 2025 (before its estimated July 31, 2026 completion). Its status may not reflect the trial's current state.
Summary
This is a single-arm, open label, multi-center clinical study to evaluate the safety, tolerability and immunogenicity HPV16 targeted mRNA therapeutic vaccine (NWRD09) in HPV16 related cervical high-grade squamous intraepithelial lesions (HSlL).
Trial Details
NCT Number NCT07047989
Lead Sponsor Newish Biotech (Wuxi) Co., Ltd.
Conditions High-grade Squamous Intraepithelial Lesion (HSIL)
Enrollment 9 participants
Start Date 2025-06-12
Primary Completion 2026-07-31 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-07-02